Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients ...
Delta-Fly Pharma's Phase I/II trial of DFP-10917 combined with Venetoclax for AML patients received FDA approval in April 2024, with the first patient enrolled at the University of Virginia Hospital. The study aims to compare the combo-therapy's efficacy with current standard AML therapy, targeting a CR rate and PFS. Post-trial success, Delta-Fly Pharma plans to collaborate with a mega pharmaceutical company for an NDA.
Reference News
Delta-Fly Pharma's Phase I/II trial of DFP-10917 combined with Venetoclax for AML patients received FDA approval in April 2024, with the first patient enrolled at the University of Virginia Hospital. The study aims to compare the combo-therapy's efficacy with current standard AML therapy, targeting a CR rate and PFS. Post-trial success, Delta-Fly Pharma plans to collaborate with a mega pharmaceutical company for an NDA.